167 related articles for article (PubMed ID: 2265474)
1. H-ras activation and ras p21 expression in bladder tumors induced in F344/NCr rats by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Enomoto T; Ward JM; Perantoni AO
Carcinogenesis; 1990 Dec; 11(12):2233-8. PubMed ID: 2265474
[TBL] [Abstract][Full Text] [Related]
2. Activation of H-ras oncogene in rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Fujita J; Ohuchi N; Ito N; Reynolds SH; Yoshida O; Nakayama H; Kitamura Y
J Natl Cancer Inst; 1988 Mar; 80(1):37-43. PubMed ID: 3276902
[TBL] [Abstract][Full Text] [Related]
3. Absence of ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N-(4-hydroxybutyl)nitrosamine.
Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Smith RA; Cohen SM
Carcinogenesis; 1992 Dec; 13(12):2281-5. PubMed ID: 1473235
[TBL] [Abstract][Full Text] [Related]
4. Activating missense mutations in Ha-ras-1 genes in a malignant subset of bladder lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine or N-[4-(5-nitro-2-furanyl)-2-thiazolyl]formamide.
Jones RF; Debiec-Rychter M; Zukowski K; Wang CY
Mol Carcinog; 1990; 3(6):393-402. PubMed ID: 2278634
[TBL] [Abstract][Full Text] [Related]
5. Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis.
Ota T; Asamoto M; Toriyama-Baba H; Yamamoto F; Matsuoka Y; Ochiya T; Sekiya T; Terada M; Akaza H; Tsuda H
Carcinogenesis; 2000 Jul; 21(7):1391-6. PubMed ID: 10874018
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation adduct formation and H-ras gene mutations in progression of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors caused by a single exposure to N-methyl-N-nitrosourea.
Shibata MA; Shirai T; Ogawa K; Takahashi S; Wild CP; Montesano R; Tsuda H; Ito N
Carcinogenesis; 1994 Dec; 15(12):2965-8. PubMed ID: 8001265
[TBL] [Abstract][Full Text] [Related]
7. H-ras mutations in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and sodium saccharin, sodium ascorbate, or related salts.
Masui T; Mann AM; Macatee TL; Okamura T; Garland EM; Fujii H; Pelling JC; Cohen SM
Cancer Res; 1991 Jul; 51(13):3471-5. PubMed ID: 2054786
[TBL] [Abstract][Full Text] [Related]
8. Point mutation in codons 12 and 61 of the Ha-ras gene in rat urinary bladder carcinomas induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.
Masui T; Mann AM; Garland EM; Okamura T; Johansson PL; Cohen SM
Mol Carcinog; 1990; 3(4):210-5. PubMed ID: 2206284
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Masui T; Don I; Takada N; Ogawa K; Shirai T; Fukushima S
Carcinogenesis; 1994 Oct; 15(10):2379-81. PubMed ID: 7955081
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.
Lee CC; Yamamoto S; Wanibuchi H; Wada S; Sugimura K; Kishimoto T; Fukushima S
Cancer Res; 1997 Nov; 57(21):4765-76. PubMed ID: 9354438
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity in (LewisxF344)F1 rat urinary bladder tumors induced with N-butyl-N-(4-hydroxybutyl)nitrosamine followed by dimethylarsinic acid or sodium L-ascorbate.
Chen T; Na Y; Wanibuchi H; Yamamoto S; Lee CC; Fukushima S
Jpn J Cancer Res; 1999 Aug; 90(8):818-23. PubMed ID: 10543252
[TBL] [Abstract][Full Text] [Related]
12. p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine.
Masui T; Dong Y; Yamamoto S; Takada N; Nakanishi H; Inada K; Fukushima S; Tatematsu M
Cancer Lett; 1996 Jul; 105(1):105-12. PubMed ID: 8689624
[TBL] [Abstract][Full Text] [Related]
13. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine.
Yamamoto S; Masui T; Murai T; Mori S; Oohara T; Makino S; Fukushima S; Tatematsu M
Carcinogenesis; 1995 Oct; 16(10):2363-8. PubMed ID: 7586136
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Harvey ras oncogene point mutations and their expression in methylbenzylnitrosamine-induced esophageal tumorigenesis.
Barch DH; Jacoby RF; Brasitus TA; Radosevich JA; Carney WP; Iannaccone PM
Carcinogenesis; 1991 Dec; 12(12):2373-7. PubMed ID: 1747941
[TBL] [Abstract][Full Text] [Related]
15. Sequencing analysis of Ha-, Ki-, and N-ras genes in rat urinary bladder tumors induced by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) and sodium saccharin.
Masui T; Mann AM; Borgeson CD; Garland EM; Okamura T; Fujii H; Pelling JC; Cohen SM
Teratog Carcinog Mutagen; 1993; 13(5):225-33. PubMed ID: 7905676
[TBL] [Abstract][Full Text] [Related]
16. p53 and H-ras mutations and microsatellite instability in renal pelvic carcinomas of NON / Shi mice treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine: different genetic alteration from urinary bladder carcinoma.
Gen H; Yamamoto S; Morimura K; Min W; Mitsuhashi M; Murai T; Mori S; Hosono M; Oohara T; Makino S; Wanibuchi H; Fukushima S
Jpn J Cancer Res; 2001 Dec; 92(12):1278-83. PubMed ID: 11749692
[TBL] [Abstract][Full Text] [Related]
17. Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
Watatani M; Perantoni AO; Reed CD; Enomoto T; Wenk ML; Rice JM
Cancer Res; 1989 Mar; 49(5):1103-9. PubMed ID: 2645046
[TBL] [Abstract][Full Text] [Related]
18. Direct DNA sequencing of the rat neu oncogene transmembrane domain reveals no mutation in urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine, N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide or N-methyl-N-nitrosourea.
Masui T; Mann AM; Macatee TL; Garland EM; Okamura T; Smith RA; Cohen SM
Carcinogenesis; 1991 Oct; 12(10):1975-8. PubMed ID: 1682063
[TBL] [Abstract][Full Text] [Related]
19. Lack of involvement of p53 gene mutations in N-methyl-N-nitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin.
Ozaki M; Shibata MA; Takahashi S; Orita SI; Kawabe M; Shirai T
Cancer Lett; 1997 May; 115(2):249-55. PubMed ID: 9149132
[TBL] [Abstract][Full Text] [Related]
20. H-ras p21 and peanut lectin immunoreactivity of hyperplastic, preneoplastic and neoplastic urinary bladder lesions in rats.
Ward JM; Hagiwara A; Tsuda H; Tatematsu M; Ito N
Jpn J Cancer Res; 1988 Feb; 79(2):152-5. PubMed ID: 3130347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
